Sujets)
Malformations multiples/diagnostic , Adolescent , Score d'Apgar , Cornée/malformations , Malformations crâniofaciales/diagnostic , Oreille/malformations , Issue fatale , Femelle , Âge gestationnel , Anomalies morphologiques de la main/diagnostic , Hernie diaphragmatique/diagnostic , Humains , Nouveau-né , Mâle , Cou/malformations , Nez/malformations , Grossesse , Issue de la grossesse , Syndrome , Échographie prénatale/méthodesSujets)
Benzothiadiazines , Bronchodilatateurs/effets indésirables , Maladies chez les jumeaux , Diurétiques , Humains , Hyponatrémie/induit chimiquement , Syndrome de sécrétion inappropriée d'ADH/induit chimiquement , Nouveau-né , Ventilation artificielle , Syndrome de détresse respiratoire du nouveau-né/traitement médicamenteux , Inhibiteurs du symport chlorure sodium/effets indésirables , Théophylline/effets indésirablesRésumé
OBJECTIVE: To evaluate safety and efficacy of recombinant human erythropoietin (r-HuEPO)in reducing the need for red cell transfusions in anemia of prematurity. METHODS: forty -two preterm infants (gestational age <32 weeks) were randomly assigned to a "treatment" group (r-HuEPO 400 units/kg every alternate day * 10 doses) or "no treatment" (control) group. All infants on enteral feeds received oral iron 3 mg/kg/day, graded up to 6 mg/kg/day. RESULTS: Higher reticulocyte counts in week 2 and 3 and higher hemoglobin levels in week 4 were noted after treatment with r-HuEPO. Despite stumulated erythropoiesis, the frequency of transfusions could not be reduced with r-HuEPO therapy.Overall, Phlebotomy losses, frequency and volume of redcell transfusions were significantly more in neonates with birthweight <1000 grams compared with those with birthweight >1000 grams (p<0.05). Associated side effects of r-HuEPO such as neutropenia,sepsis, hypertension or increased risk of late death did not occur. CONCLUSION:r-HuEPO therapy was safe without any side effects.Inability of r-HuEPO therapy to minimize red cell transfusions for anemia of prematurity may be explained by a relatively strict red-cell transfusion policy and the desired degree of treatment effect.